Esophageal Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Esophageal Squamous Cell Carcinoma (90)

Esophageal Adenocarcinoma (39)

Esophageal Squamous Cell Carcinoma (90)

Esophageal Adenocarcinoma (39)

›

No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
PD-L1 expression	Esophageal Cancer	PD-L1 expression	Esophageal Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	tislelizumab-jsgr Sensitive: A1 - Approval tislelizumab-jsgr Sensitive : A1	tislelizumab-jsgr Sensitive: A1 - Approval tislelizumab-jsgr Sensitive : A1
HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	HER-2 negative + PD-L1 expression	Esophageal Adenocarcinoma	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1	serplulimab Sensitive: A1 - Approval serplulimab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	sugemalimab Sensitive: A1 - Approval sugemalimab Sensitive : A1	sugemalimab Sensitive: A1 - Approval sugemalimab Sensitive : A1
MSI-H/dMMR	Esophageal Cancer	MSI-H/dMMR	Esophageal Cancer	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Esophageal Adenocarcinoma	No biomarker	Esophageal Adenocarcinoma	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2	ramucirumab Sensitive: A2 - Guideline ramucirumab Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	docetaxel + irinotecan Sensitive: A2 - Guideline docetaxel + irinotecan Sensitive : A2	docetaxel + irinotecan Sensitive: A2 - Guideline docetaxel + irinotecan Sensitive : A2
HER-2 positive	Esophageal Adenocarcinoma	HER-2 positive	Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
HER-2 overexpression	Esophageal Adenocarcinoma	HER-2 overexpression	Esophageal Adenocarcinoma	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2	trastuzumab Sensitive: A2 - Guideline trastuzumab Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	5-fluorouracil + irinotecan Sensitive: A2 - Guideline 5-fluorouracil + irinotecan Sensitive : A2	5-fluorouracil + irinotecan Sensitive: A2 - Guideline 5-fluorouracil + irinotecan Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2	irinotecan Sensitive: A2 - Guideline irinotecan Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2
No biomarker	Esophageal Cancer	No biomarker	Esophageal Cancer	capecitabine + oxaliplatin Sensitive: A2 - Guideline capecitabine + oxaliplatin Sensitive : A2	capecitabine + oxaliplatin Sensitive: A2 - Guideline capecitabine + oxaliplatin Sensitive : A2
NTRK3 fusion	Esophageal Cancer	NTRK3 fusion	Esophageal Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Esophageal Cancer	NTRK2 fusion	Esophageal Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2

Esophageal Cancer

Associations(195)

Associations
(195)